Inkeun Park


Ontology type: schema:Person     


Person Info

NAME

Inkeun

SURNAME

Park

Publications in SciGraph latest 50 shown

  • 2018-12 The clinical implications of G1-G6 transcriptomic signature and 5-gene score in Korean patients with hepatocellular carcinoma in BMC CANCER
  • 2018-12 FGFR1 expression defines clinically distinct subtypes in pancreatic cancer in JOURNAL OF TRANSLATIONAL MEDICINE
  • 2018-12 Genomics of drug sensitivity in bladder cancer: an integrated resource for pharmacogenomic analysis in bladder cancer in BMC MEDICAL GENOMICS
  • 2017-01 The role of adjuvant therapy after R0 resection for patients with intrahepatic and perihilar cholangiocarcinomas in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2016-11 Evaluation of sarcopenia in small-cell lung cancer patients by routine chest CT in SUPPORTIVE CARE IN CANCER
  • 2016-08 Pazopanib versus sunitinib for the treatment of metastatic renal cell carcinoma patients with poor-risk features in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2016-05 Role of adjuvant therapy after R0 resection for patients with distal cholangiocarcinoma in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2016-04 Prognostic tissue biomarker exploration for patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor receptor tyrosine kinase inhibitors in TUMOR BIOLOGY
  • 2016-02 Long-term outcomes of tyrosine kinase inhibitor discontinuation in patients with metastatic renal cell carcinoma in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2016-01 Risk factors for selection of patients at high risk of recurrence or death after complete surgical resection in stage I gastric cancer in GASTRIC CANCER
  • 2015-12 Low-dose capecitabine plus trastuzumab as first-line treatment in patients 75 years of age or older with HER2-positive advanced gastric cancer: a pilot study in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2015-05 Vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) rechallenge for patients with metastatic renal cell carcinoma after treatment failure using both VEGFR-TKI and mTOR inhibitor in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2014-12 Epidermal growth factor receptor (EGFR) exon 20 mutations in non-small-cell lung cancer and resistance to EGFR-tyrosine kinase inhibitors in INVESTIGATIONAL NEW DRUGS
  • 2014-11 Non-surgical treatment versus radical esophagectomy for clinical T1N0M0 esophageal carcinoma: a single-center experience in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2014-08 Active surveillance for metastatic or recurrent renal cell carcinoma in JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
  • 2014-06 Clinical significance of Ki-67 and p53 expression in curatively resected non-small cell lung cancer in TUMOR BIOLOGY
  • 2014-04 Phase I and pharmacodynamic study of vorinostat combined with capecitabine and cisplatin as first-line chemotherapy in advanced gastric cancer in INVESTIGATIONAL NEW DRUGS
  • 2014-01 A randomized phase II study of weekly docetaxel/cisplatin versus weekly docetaxel/oxaliplatin as first-line therapy for patients with advanced gastric cancer in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2013-10 Erratum to: Prognostic factors of metastatic renal cell carcinoma with extensive sarcomatoid component in JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
  • 2013-10 A phase II study of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy followed by surgery and adjuvant S-1 chemotherapy in potentially resectable gastric or gastroesophageal junction adenocarcinoma in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2013-10 Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib in BRITISH JOURNAL OF CANCER
  • 2013-05 Prognostic factors of metastatic renal cell carcinoma with extensive sarcomatoid component in JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
  • 2013-04 Adjuvant chemotherapy for gastric cancer: a randomised phase 3 trial of mitomycin-C plus either short-term doxifluridine or long-term doxifluridine plus cisplatin after curative D2 gastrectomy (AMC0201) in BRITISH JOURNAL OF CANCER
  • 2012-12 Comparative efficacy of vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin (mTOR) inhibitor as second-line therapy in patients with metastatic renal cell carcinoma after the failure of first-line VEGF TKI in MEDICAL ONCOLOGY
  • 2012-10 Safety and feasibility of adjuvant chemotherapy with S-1 for Korean patients with curatively resected advanced gastric cancer in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2012-04 Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma and poor risk features in JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
  • 2010-02 Phase I/II and pharmacokinetic study of S-1 and oxaliplatin in previously untreated advanced gastric cancer in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "affiliation": [
          {
            "affiliation": {
              "id": "https://www.grid.ac/institutes/grid.411653.4", 
              "type": "Organization"
            }, 
            "isCurrent": true, 
            "type": "OrganizationRole"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.256155.0", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.413967.e", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.411635.4", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.411652.5", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.267370.7", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.411627.7", 
            "type": "Organization"
          }
        ], 
        "familyName": "Park", 
        "givenName": "Inkeun", 
        "id": "sg:person.0627312245.16", 
        "identifier": {
          "name": "orcid_id", 
          "type": "PropertyValue", 
          "value": [
            "0000-0003-3064-7895"
          ]
        }, 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0627312245.16", 
          "https://orcid.org/0000-0003-3064-7895"
        ], 
        "sdDataset": "persons", 
        "sdDatePublished": "2019-03-07T13:11", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-uberresearch-data-dimensions-researchers-20181010/20181011/dim_researchers/base/researchers_1015.json", 
        "type": "Person"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/person.0627312245.16'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/person.0627312245.16'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/person.0627312245.16'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/person.0627312245.16'


     

    This table displays all metadata directly associated to this object as RDF triples.

    33 TRIPLES      11 PREDICATES      19 URIs      8 LITERALS      3 BLANK NODES

    Subject Predicate Object
    1 sg:person.0627312245.16 schema:affiliation Nb355a9a114904344849394b2ad187664
    2 https://www.grid.ac/institutes/grid.256155.0
    3 https://www.grid.ac/institutes/grid.267370.7
    4 https://www.grid.ac/institutes/grid.411627.7
    5 https://www.grid.ac/institutes/grid.411635.4
    6 https://www.grid.ac/institutes/grid.411652.5
    7 https://www.grid.ac/institutes/grid.413967.e
    8 schema:familyName Park
    9 schema:givenName Inkeun
    10 schema:identifier Nb148e86c1c9b453a94f2a95ce46b794c
    11 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0627312245.16
    12 https://orcid.org/0000-0003-3064-7895
    13 schema:sdDatePublished 2019-03-07T13:11
    14 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    15 schema:sdPublisher N6a5a6f32ae8b4774af56078ef2ae0b05
    16 sgo:license sg:explorer/license/
    17 sgo:sdDataset persons
    18 rdf:type schema:Person
    19 N6a5a6f32ae8b4774af56078ef2ae0b05 schema:name Springer Nature - SN SciGraph project
    20 rdf:type schema:Organization
    21 Nb148e86c1c9b453a94f2a95ce46b794c schema:name orcid_id
    22 schema:value 0000-0003-3064-7895
    23 rdf:type schema:PropertyValue
    24 Nb355a9a114904344849394b2ad187664 schema:affiliation https://www.grid.ac/institutes/grid.411653.4
    25 sgo:isCurrent true
    26 rdf:type schema:OrganizationRole
    27 https://www.grid.ac/institutes/grid.256155.0 schema:Organization
    28 https://www.grid.ac/institutes/grid.267370.7 schema:Organization
    29 https://www.grid.ac/institutes/grid.411627.7 schema:Organization
    30 https://www.grid.ac/institutes/grid.411635.4 schema:Organization
    31 https://www.grid.ac/institutes/grid.411652.5 schema:Organization
    32 https://www.grid.ac/institutes/grid.411653.4 schema:Organization
    33 https://www.grid.ac/institutes/grid.413967.e schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...